COL4A5 and Alport syndrome: A comprehensive NanoLuc-based investigation of known readthrough inducers in the context of a larger number of nonsense mutations in COL4A5—the gene involved in Alport syndrome—suggested the applicability of PTC readthrough therapy for a subset of mutations (at least 11 out of 49 nonsense mutations in COL4A5) [134].